(Q35877266)

English

Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide

scientific article published in September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide (English)

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

author name string

Christopher N Bredeson

1

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Mei-Jie Zhang

2

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Manza-A Agovi

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Andrea Bacigalupo

4

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Nizar J Bahlis

5

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Karen Ballen

6

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Christopher Brown

7

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

M Ahsan Chaudhry

8

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Mary M Horowitz

9

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Seira Kurian

10

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Diana Quinlan

11

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Catherine E Muehlenbien

12

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

James A Russell

13

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Lynn Savoie

14

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

J Douglas Rizzo

15

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Douglas A Stewart

16

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

publication date

1 September 2008

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Biology of Blood and Marrow Transplantation

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

14

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

993-1003

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

27 July 2018

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

27 July 2018

Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

27 July 2018

Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

27 July 2018

Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

27 July 2018

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

27 July 2018

Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

27 July 2018

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

27 July 2018

High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

24 September 2018

Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

24 September 2018

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

24 September 2018

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

24 September 2018

Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

24 September 2018

Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

24 September 2018

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

24 September 2018

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

24 September 2018

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

24 September 2018

Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

24 September 2018

Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

24 September 2018

Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

24 September 2018

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321981

24 September 2018

Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.BBMT.2008.06.009

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35877266&oldid=1522765638"